• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    (OP:MDXXF)

    0.1063 UNCHANGED
    Streaming Delayed Price Updated: 12:06 PM EDT, May 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.1063
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.1063
    Today's Range 0.1063 - 0.1063
    52wk Range 0.0614 - 0.1425
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
    Definitive Agreement Targeted for Execution by June 2026 
    From PharmAla Biotech
    Via GlobeNewswire

    Performance

    YTD
    +21.1%
    +21.1%
    1 Month
    +55.4%
    +55.4%
    3 Month
    +50.8%
    +50.8%
    6 Month
    +22.6%
    +22.6%
    1 Year
    +4.9%
    +4.9%

    More News

    Read More
    News headline image
    PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    Cortexa Advances Commercialisation of MDMA Supply in Australia
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    Small Cap Growth Virtual Investor Conference Agenda Announced for October 16th
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    Small Cap Growth Virtual Investor Conference Agenda Announced for October 16th
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    PharmAla Contracts with Partner to Act as US Distributor
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    PharmAla Biotech To Supply LaNeo MDMA For Mt. Sinai Clinical Trial ↗
    Via Benzinga
    News headline image
    PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial ↗
    Via Benzinga
    News headline image
    PharmAla Biotech To Supply MDMA For Harvard's Maclean Hospital Clinical Trial ↗
    Via Benzinga
    News headline image
    PharmAla Biotech Partners With Johns Hopkins University For MDMA Clinical Trials, Terminates Red Light Holland Contract ↗
    Via Benzinga
    News headline image
    PharmAla Launches MDMA Clinical Trial Tool for Researchers
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale ↗
    Via Benzinga
    News headline image
    Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More ↗
    Via Benzinga
    News headline image
    Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
    From PharmAla Biotech
    Via GlobeNewswire
    News headline image
    Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More ↗
    Via Benzinga

    Frequently Asked Questions

    Is MDXXF publicly traded?
    Yes, MDXXF is publicly traded.
    What exchange does MDXXF trade on?
    MDXXF trades on the OTC Traded
    What is the ticker symbol for MDXXF?
    The ticker symbol for MDXXF is MDXXF on the OTC Traded
    What is the current price of MDXXF?
    The current price of MDXXF is 0.1063
    When was MDXXF last traded?
    The last trade of MDXXF was at 05/14/26 12:06 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.